# In vivo Drug Testing of Pediatric CNS Tumors Using Patient Derived Orthotopic Xenograft Models

> **NIH NIH U01** · LURIE CHILDREN'S HOSPITAL OF CHICAGO · 2021 · $387,858

## Abstract

PROJECT SUMMARY/ABSTRACT
This application is prepared for an extension of our previously funded research proposal that was in response
to RFA-CA-14-018, Pediatric Preclinical Testing Consortium Research Programs (U01), and specifically to
Type B: research Program for tumors of central nervous system (CNS) in vivo testing. Brain tumor is the
leading cause of cancer-related death in children. One of the challenges in clinical drug development is how to
effectively prioritize drug candidates to ensure clinical success in cancer patients. As drug candidates are more
numerous than the small number of patients, it is essential to perform comprehensive pre-clinical testing to
identify the investigational agents that are most likely to be effective in the clinic. However, such effort has
been blocked for many years due to the lack of clinically relevant and molecularly accurate model systems.
Fortunately, we have established a large panel (>130) of patient derived orthotopic xenograft (PDOX) models
of pediatric brain tumors through direct injection of patient tumor specimens into the brains of SCID mice.
These PDOX models are shown to have replicated the histopathological features, invasive phenotypes and
major genetic abnormalities (gene expression, DNA copy number and gene mutations) of the original primary
tumors even during serial sub-transplantations in vivo in mouse brains. The xenograft tumor cells can also be
cryopreserved for sustained and on-demand supply of tumorigenic PDOX cells. This capacity combined with
our optimized surgical procedure, with which we can implant up to 260 mice per day, makes it possible for us
to test multiple (e.g., 6-10) drugs per year for every tumor type. Our objective is therefore to make use of this
unique panel of PDOX models to examine therapeutic efficacy of new agents and to analyze mechanisms of
action and therapy resistance in high grade glioma, medulloblastoma and ependymoma. Our hypothesis is that
these patient-specific PDOX tumors will respond to anti-cancer therapies similarly to the corresponding human
primary tumors, and the effective agents identified through this system would have better chances of clinical
success. To test this hypothesis, we will perform a series of in vitro and in vivo assays to achieve the following
aims: 1) to identify genetically accurate candidate PDOX models that bear the therapeutic target(s) of new
investigational drugs through data mining of our mouse model molecular characterization databases; 2) to
select the most responsive models through functional in vitro screening to determine time- and dose-
responses; 3) to demonstrate therapeutic efficacy of new investigational drugs in multiple target-bearing PDOX
models; and 4) to perform detailed analysis of cellular and molecular mechanisms of cell killing as well as the
causes of therapy resistance both in vitro and in vivo. Our novel panel of PDOX mouse models represents a
broad spectrum of genetic abnormalities of pediatric ...

## Key facts

- **NIH application ID:** 10302832
- **Project number:** 3U01CA199288-05S2
- **Recipient organization:** LURIE CHILDREN'S HOSPITAL OF CHICAGO
- **Principal Investigator:** Xiaonan Li
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $387,858
- **Award type:** 3
- **Project period:** 2021-01-01 → 2021-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10302832

## Citation

> US National Institutes of Health, RePORTER application 10302832, In vivo Drug Testing of Pediatric CNS Tumors Using Patient Derived Orthotopic Xenograft Models (3U01CA199288-05S2). Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/grant/nih/10302832. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*